[HTML][HTML] The venetoclax/azacitidine combination targets the disease clone in acute myeloid leukemia, being effective and safe in a patient with COVID-19
A Cristiano, R Palmieri, E Fabiani, T Ottone… - … of Hematology and …, 2022 - ncbi.nlm.nih.gov
The addition of Venetoclax (VEN) to Hypomethylating agents (HMAs) significantly improves
the probability of complete remission and prolongs survival in patients with Acute Myeloid …
the probability of complete remission and prolongs survival in patients with Acute Myeloid …
How genetics can drive initial therapy choices for older patients with acute myeloid leukemia
JW Moore, N Torres, M Superdock, JH Mendler… - … treatment options in …, 2022 - Springer
Opinion statement Treatment of older adults with acute myeloid leukemia (AML) is
challenging. Therapy decisions must be guided by multiple factors including aging-related …
challenging. Therapy decisions must be guided by multiple factors including aging-related …
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine
J Feld, D Tremblay, SC Navada… - Leukemia & …, 2023 - Taylor & Francis
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are devastating
diseases that frequently rely on the use of parenteral hypomethylating agents (HMAs), either …
diseases that frequently rely on the use of parenteral hypomethylating agents (HMAs), either …
克拉屈滨联合维奈克拉及低剂量阿糖胞苷在老年AML 患者中应用的早期临床疗效及安全性分析
汪安友， 朱婷， 王丽， 蔡晓燕， 刘欣 - 临床输血与检验, 2023 - lcsxyjy.com
目的小样本量分析探讨克拉屈滨联合维奈克拉及小剂量阿糖胞苷方案在老年急性髓系白血病(
AML) 患者中应用的早期临床疗效及安全性分析. 方法选取本中心2022 年9 月—2023 年3 …
AML) 患者中应用的早期临床疗效及安全性分析. 方法选取本中心2022 年9 月—2023 年3 …
Hospital, M
S Garciaz - respiration, 2024 - europepmc.org
Venetoclax is a BH3-mimetics agent interacting with the anti-apoptotic protein BCL2,
facilitating cytochrome c release from mitochondria, subsequent caspases activation, and …
facilitating cytochrome c release from mitochondria, subsequent caspases activation, and …
[PDF][PDF] EFFECTS OF EVOFOSFAMIDE AND OTHER ANTICANCER DRUGS ON HUMAN GINGIVAL FIBROBLASTS: A REVIEW
Anticancer drugs, either cytostatic or cytotoxic, have profound effects on the oral cavity of the
human being. Oral complications caused due to anticancer drugs include oral mucositis …
human being. Oral complications caused due to anticancer drugs include oral mucositis …
Hogyan változott az akut myeloid leukaemiás betegek túlélése a terápiás lehetőségek bővülésével az elmúlt 10 évben klinikánkon?
L Gaál, E Ruff, Á Wiedemann, S Svorenj, VR Szita… - Orvosi …, 2023 - akjournals.com
Bevezetés: Az akut myeloid leukaemia (AML) nagy mortalitású hematológiai malignitás,
amelynek kezelése különösen a betegek többségét alkotó 65 év feletti korcsoportban nagy …
amelynek kezelése különösen a betegek többségét alkotó 65 év feletti korcsoportban nagy …
The microRNA signature of chemoresistance in acute myeloid leukemia
MSPS Reichelt - 2023 - ul.qucosa.de
Abstract (EN) In patients with acute myeloid leukemia (AML), cytarabine-based
chemotherapy usually achieves remission, but this is commonly followed by relapse and …
chemotherapy usually achieves remission, but this is commonly followed by relapse and …
[HTML][HTML] Прогностическое значение соматических мутаций в генах эпигенетической регуляции при острых миелоидных лейкозах в реальной клинической …
АА Шатилова, ИГ Будаева, АВ Петухов… - Клиническая …, 2023 - cyberleninka.ru
Цель. Оценить частоту и влияние на прогноз мутаций в генах DNMT3A, IDH1, IDH2 и
ASXL1 в изолированном варианте и в сочетании с известными хромосомными …
ASXL1 в изолированном варианте и в сочетании с известными хромосомными …
[PDF][PDF] The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML …
L Urwanisch, MS Unger, H Sieberer, HH Dang… - 2023 - bia.unibz.it
Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by altered
myeloid progenitor cell proliferation and differentiation. As in many other cancers, epigenetic …
myeloid progenitor cell proliferation and differentiation. As in many other cancers, epigenetic …